One of the critical findings of our current study is that a small molecule PARP inhibitor (i.e., olaparib) suppresses the activity of neoplastic MYC transcription factor, especially in cancer cells spontaneously acquired cisplatin resistance. Here, PARP1 is linked to cancer.